Akeso, Inc.
9926.HK · Hong Kong Stock Exchange · HKD
89,10HKD
+0,40 (+0,45 %)Stand 10. Nov., 8:08
Kennzahlen
- Eröffnung
- 92,00
- Vortag
- 88,70
- Tagesspanne
- 88,90 – 92,20
- 52 Wochen
- 74,50 – 156,00
- Volumen
- 7 Mio.
- Ø Volumen
- 11,41 Mio.
- Börsenwert
- 80,59 Mrd. HKD
- KGV
- -72,9
- Gewinn je Aktie (TTM)
- -2,00
- Dividendenrendite
- 0,0 %
- Beta
- 0,0
- Nächste Zahlen
- 31. März 2027
Finanzen
| CNY | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 2,98 Mrd. | 2,12 Mrd. | 4,53 Mrd. | 837,66 Mio. | 225,63 Mio. |
| Herstellungskosten | 635,42 Mio. | 289,04 Mio. | 133,25 Mio. | 103,11 Mio. | 30,22 Mio. |
| Bruttogewinn | 2,34 Mrd. | 1,83 Mrd. | 4,39 Mrd. | 734,54 Mio. | 195,41 Mio. |
| Forschung und Entwicklung | 1,53 Mrd. | 1,19 Mrd. | 1,25 Mrd. | 1,32 Mrd. | 1,12 Mrd. |
| Vertrieb und Verwaltung | 1,69 Mrd. | 1,21 Mrd. | 1,09 Mrd. | 751,67 Mio. | 422,67 Mio. |
| Operatives Ergebnis | −918,23 Mio. | −570,42 Mio. | 2,04 Mrd. | −1,34 Mrd. | −1,35 Mrd. |
| EBITDA | −656,33 Mio. | −536,34 Mio. | 2,17 Mrd. | −1,27 Mrd. | −1,31 Mrd. |
| Nettogewinn | −1,08 Mrd. | −514,52 Mio. | 2,03 Mrd. | −1,17 Mrd. | −1,07 Mrd. |
| Gewinn je Aktie (verwässert) | -1,20 | -0,60 | 2,42 | -1,42 | -1,32 |
Bewertung
Letzte 12 Monate
- KGV
- -72,9
- Kurs-Umsatz-Verhältnis
- 20,2
- Kurs-Buchwert-Verhältnis
- 8,2
- PEG
- 4,5
- Bruttomarge
- 76,0 %
- Operative Marge
- −22,4 %
- Nettomarge
- −28,0 %
- Verschuldungsgrad
- 0,6
- EV/EBITDA
- -83,3
- Eigenkapitalrendite
- −10,9 %
- Kapitalrendite (ROIC)
- −5,3 %
- Free-Cashflow-Rendite
- −1,8 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 78,7 % | 86,4 % | 97,1 % | 87,7 % | 86,6 % |
| Operative Marge | −30,8 % | −26,9 % | 45,2 % | −160,0 % | −598,4 % |
| Nettomarge | −36,4 % | −24,2 % | 44,8 % | −139,5 % | −476,4 % |
| KGV | -84,6 | -95,0 | 17,4 | -26,7 | -21,0 |
| Kurs-Umsatz-Verhältnis | 30,8 | 22,8 | 7,8 | 37,4 | 100,1 |
| Kurs-Buchwert-Verhältnis | 10,1 | 7,1 | 7,5 | 11,9 | 7,1 |
| Verschuldungsgrad | 0,5 | 0,6 | 0,6 | 0,7 | 0,3 |
| Liquidität 3. Grades | 5,1 | 5,2 | 4,7 | 2,2 | 4,8 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 87,37 Mrd. | 45,58 Mrd. | 34,17 Mrd. | 31,11 Mrd. | 20,81 Mrd. |
| EV/EBITDA | -133,1 | -85,0 | 15,7 | -24,4 | -15,9 |
| Eigenkapitalrendite | −12,0 % | −7,6 % | 43,2 % | −44,3 % | −34,0 % |
| Kapitalrendite (ROIC) | −6,4 % | −4,9 % | 24,4 % | −29,2 % | −32,1 % |
| Free-Cashflow-Rendite | −2,0 % | −2,3 % | 4,5 % | −6,4 % | −7,6 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +40,2 % | −53,1 % | +440,3 % | +271,3 % | 0,0 % |
| Bruttogewinn | +27,6 % | −58,2 % | +498,1 % | +275,9 % | +10.368,5 % |
| Operatives Ergebnis | −61,0 % | −127,9 % | +252,5 % | +0,7 % | −31,9 % |
| Nettogewinn | −110,7 % | −125,4 % | +273,6 % | −8,7 % | −3,7 % |
| Gewinn je Aktie | −100,0 % | −124,8 % | +270,4 % | −7,6 % | +20,0 % |
| Freier Cashflow | −64,0 % | −170,1 % | +178,8 % | −17,7 % | −61,3 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 5,3 Mrd. | 8,23 Mrd. | 11,69 Mrd. |
| Umsatz (Tief – Hoch) | 4,52 Mrd. – 6,63 Mrd. | 6,27 Mrd. – 9,6 Mrd. | 9,46 Mrd. – 14,18 Mrd. |
| Gewinn je Aktie (Ø) | -0,35 | 0,96 | 2,59 |
| Gewinn je Aktie (Tief – Hoch) | -13,64 – 9,27 | 0,41 – 1,63 | 0,34 – 4,77 |
| Analysten | 16 | 16 | 22 |
Quartalszahlen
Nächste Zahlen: 31. März 2027| Aug. 2026 | März 2026 | Aug. 2025 | März 2025 | Aug. 2024 | März 2024 | Aug. 2023 | März 2023 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | -1,28 |
| Gewinn je Aktie · Tatsächlich | -0,53 | -0,65 | -0,70 | -0,34 | -0,30 | -0,66 | 3,26 | -0,73 |
| Abweichung | – | – | – | – | – | – | – | +42,74 % |
| Umsatz · Tatsächlich | 2,08 Mrd. | 1,86 Mrd. | 1,54 Mrd. | 1,17 Mrd. | 1,1 Mrd. | 940,11 Mio. | 3,98 Mrd. | 768,22 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
1541.HKImmuneOnco Biopharmaceuticals (Shanghai) Inc.2,74−1,08 %
1801.HKInnovent Biologics, Inc.88,30+2,14 %
2142.HKHBM Holdings Limited11,06+2,98 %
2595.HKGenFleet Therapeutics (Shanghai) Inc.23,96+6,39 %
2696.HKShanghai Henlius Biotech, Inc.50,15+0,74 %
3378.HKHanx Biopharmaceuticals (Wuhan) Co., Ltd.25,50−5,35 %
6990.HKSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.463,80−0,26 %
6996.HKAntengene Corporation Limited2,82+4,64 %
Über das Unternehmen
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
Führung
- Yu XiaFounder, Chief Executive Officer, President & Chairwoman
- Jing MinSenior Vice President
- Mingxiu HuSenior Vice President
- Xinfeng ZhangSenior Vice President
- Baiyong LiCo-Founder, Executive Vice President, CSO & Executive Director
- Peng ZhangCo-Founder, Senior Vice President & Executive Director
- CEO
- Yu Xia
- Mitarbeitende
- 4.082
- Hauptsitz
- Zhongshan, GD, CN
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 24. Apr. 2020
- Website
- akesobio.com
Nachrichten
- PRNewsWire · 25. Okt., 11:31Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
- PRNewsWire · 10. Okt., 0:41First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
- PRNewsWire · 2. Sept., 17:00Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.